Leap Therapeutics, Inc. (LPTX) News
Filter LPTX News Items
LPTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
LPTX News Highlights
- For LPTX, its 30 day story count is now at 2.
- Over the past 20 days, the trend for LPTX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest LPTX News From Around the Web
Below are the latest news stories about LEAP THERAPEUTICS INC that investors may wish to consider to help them evaluate LPTX as an investment opportunity.
Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers SymposiumLeap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the Company will be presenting new data in second-line patients with advanced colorectal cancer from the DeFianCe study, a Phase 2 study evaluating DKN-01, Leap's anti-Dickkopf-1 (DKK1) antibody, in combination with standard of care bevacizumab and chemotherapy at the upcoming 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer |
Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare ConferenceLeap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference in New York, NY. |
Leap Therapeutics Reports Third Quarter 2023 Financial ResultsLeap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2023. |
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An AnalysisNEW YORK, NY / ACCESSWIRE / October 24, 2023 / The biotech sector, known for its exponential growth potential, is currently facing highly challenging market conditions. Influences like rising inflation, geopolitical tensions, and looming economic ... |
These 2 “Strong Buy” Penny Stocks Could Gain Over 500%, Says BairdIn the classic tune by Kenny Rogers, ‘The Gambler,’ he sang, ‘Every hand’s a winner and every hand’s a loser…’ These words hold valuable wisdom that should resonate with every investor. Regardless of your chosen investment strategy, achieving success in the stock market ultimately hinges on mastering the art of balancing risk and reward. Few segments of the stock market offer a higher potential return for the risk involved than the penny stocks, those equities priced at $5 or less. These are sto |
Leap Therapeutics to Participate at Upcoming Investor ConferencesLeap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will participate in two upcoming investor conferences: |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayInvestors will want to get ready for another busy day of trading as we cover the biggest pre-market stock movers for Wednesday! |
Leap Therapeutics Reports Second Quarter 2023 Financial ResultsLeap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for second quarter ended June 30, 2023. |
10 Most Promising Penny Stocks According to AnalystsIn this article, we will take a look at the 10 most promising penny stocks according to analysts. To see more such companies, go directly to 5 Most Promising Penny Stocks According to Analysts. Innovation is what drives human societies forward. Major companies of today were once small companies working on innovative and disruptive ideas. […] |
Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer PatientsLeap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that, based on the early efficacy and momentum seen in the enrollment of 33 patients with colorectal cancer (CRC) in its DeFianCe study, it has initiated the 130 patient randomized controlled Part B of the Phase 2 study. The study evaluates Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with standard of care bevacizumab and chemotherapy a |